Prenosis hopes to tackle sepsis with Immunix, an "assisted intelligence" system that provides ImmunoScore, a rating of a patient's chances of developing the life-threatening condition along with 30-day mortality, elongated hospital stay, and 30-day readmission to the hospital. It employs a machine learning algorithm and holistic input data from 23 parameters including three biomarkers (Interleukin-6, procalcitonin, and C-reactive protein) to help profile the patient's underlying biological state accurately.
Also, under a recently expanded partnership with Roche Diagnostics, Prenosis will add to its core dataset, and the two companies will work toward FDA clearance for the Prenosis Sepsis Immunoscore and the Roche Elecsys IL-6 Assay. The Prenosis Sepsis Immunoscore diagnostic combines Elecsys IL-6 with other sepsis biomarkers and clinical risk parameters and aims to predict, diagnose, and treat sepsis earlier, according to a news release. The Roche Elecsys IL-6 assay measures interleukin-6 concentrations from patient plasma or serum samples. Elecsys IL-6 is a predictive biomarker essential in the disease pathways of many inflammatory conditions, including sepsis thanks to its early elevation.
"We are excited to expand upon our relationship with Roche and to accelerate the birth of 'prenostic' testing to help reduce the burden of the sepsis crisis," said Prenosis CEO and Co-Founder Bobby Reddy, Jr. in the release. "Prenostics, or predictive and precise diagnostics, test the right patient parameters at the right time for the right clinical situation/context. The Prenosis platform is ushering in a new era in pre-emptive diagnostic testing. The implications are groundbreaking: we have the ability to accurately and cost-effectively predict disease much earlier, enabling prevention instead of treatment."